Exelixis cuts 175 staffers to prioritize late-stage drug development
Exelixis is laying off 175 employees, or 13% of its workforce, to “rebalance resources” with a focus on candidates closer to market.
The company appears …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
